Generic drug companies have successfully challenged two key Novo Nordisk patents related to the tablet formulation of semaglutide, a blockbuster drug for diabetes (Rybelsus) and weight loss (Wegovy). The European Patent Office\u2019s Boards of Appeal revoked patents EP 2 827 845 and EP 2 827 885, which protected semaglutide’s oral composition. Novo Nordisk maintains that other patents in its portfolio continue to protect the drug.<\/p>\n\n\n\n
We are pleased that we have successfully represented Hexal in this case. This text is a summary of an article published by JUVE Patent. The full text of the article is available here.<\/a><\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-44070","presseberichte","type-presseberichte","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/44070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte"}],"about":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/types\/presseberichte"}],"version-history":[{"count":2,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/44070\/revisions"}],"predecessor-version":[{"id":44104,"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/presseberichte\/44070\/revisions\/44104"}],"wp:attachment":[{"href":"https:\/\/www.maiwald.eu\/cn\/wp-json\/wp\/v2\/media?parent=44070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}